Connaughton, Dervla M.
Bhai, Pratibha
Isenring, Paul
Mahdi, Mohammed
Sadikovic, Bekim
Schenkel, Laila C. http://orcid.org/0000-0002-4980-7484
Funding for this research was provided by:
Alexion Pharma Canada
Article History
Received: 3 November 2022
Revised: 14 June 2023
Accepted: 16 June 2023
First Online: 19 July 2023
Declarations
:
: Ethical review and approval was not required for this study on human participants in accordance with local legislation and institution requirements.
: Written informed consent to participate in this study was provided by the participants’ legal guardian or next of kin. Informed consent was obtained from the patient described in the case study.
: Informed consent was obtained from the participants described in the case study.
: Paul Isenring has received consultancy fees from Alexion, AstraZeneca Rare Disease. Mohammed Mahdi is an employee of Alexion, AstraZeneca Rare Disease, Canada.